Cargando…
Exacerbations of COPD
Exacerbations of chronic obstructive pulmonary disease (COPD) are defined as sustained worsening of a patient’s condition beyond normal day-to-day variations that is acute in onset, and that may also require a change in medication and/or hospitalization. Exacerbations have a significant and prolonge...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4764047/ https://www.ncbi.nlm.nih.gov/pubmed/26937187 http://dx.doi.org/10.2147/COPD.S85978 |
_version_ | 1782417342329782272 |
---|---|
author | Pavord, Ian D Jones, Paul W Burgel, Pierre-Régis Rabe, Klaus F |
author_facet | Pavord, Ian D Jones, Paul W Burgel, Pierre-Régis Rabe, Klaus F |
author_sort | Pavord, Ian D |
collection | PubMed |
description | Exacerbations of chronic obstructive pulmonary disease (COPD) are defined as sustained worsening of a patient’s condition beyond normal day-to-day variations that is acute in onset, and that may also require a change in medication and/or hospitalization. Exacerbations have a significant and prolonged impact on health status and outcomes, and negative effects on pulmonary function. A significant proportion of exacerbations are unreported and therefore left untreated, leading to a poorer prognosis than those treated. COPD exacerbations are heterogeneous, and various phenotypes have been proposed which differ in biologic basis, prognosis, and response to therapy. Identification of biomarkers could enable phenotype-driven approaches for the management and prevention of exacerbations. For example, several biomarkers of inflammation can help to identify exacerbations most likely to respond to oral corticosteroids and antibiotics, and patients with a frequent exacerbator phenotype, for whom preventative treatment is appropriate. Reducing the frequency of exacerbations would have a beneficial impact on patient outcomes and prognosis. Preventative strategies include modification of risk factors, treatment of comorbid conditions, the use of bronchodilator therapy with long-acting β(2)-agonists or long-acting muscarinic antagonists, and inhaled corticosteroids. A better understanding of the mechanisms underlying COPD exacerbations will help to optimize use of the currently available and new interventions for preventing and treating exacerbations. |
format | Online Article Text |
id | pubmed-4764047 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-47640472016-03-02 Exacerbations of COPD Pavord, Ian D Jones, Paul W Burgel, Pierre-Régis Rabe, Klaus F Int J Chron Obstruct Pulmon Dis Review Exacerbations of chronic obstructive pulmonary disease (COPD) are defined as sustained worsening of a patient’s condition beyond normal day-to-day variations that is acute in onset, and that may also require a change in medication and/or hospitalization. Exacerbations have a significant and prolonged impact on health status and outcomes, and negative effects on pulmonary function. A significant proportion of exacerbations are unreported and therefore left untreated, leading to a poorer prognosis than those treated. COPD exacerbations are heterogeneous, and various phenotypes have been proposed which differ in biologic basis, prognosis, and response to therapy. Identification of biomarkers could enable phenotype-driven approaches for the management and prevention of exacerbations. For example, several biomarkers of inflammation can help to identify exacerbations most likely to respond to oral corticosteroids and antibiotics, and patients with a frequent exacerbator phenotype, for whom preventative treatment is appropriate. Reducing the frequency of exacerbations would have a beneficial impact on patient outcomes and prognosis. Preventative strategies include modification of risk factors, treatment of comorbid conditions, the use of bronchodilator therapy with long-acting β(2)-agonists or long-acting muscarinic antagonists, and inhaled corticosteroids. A better understanding of the mechanisms underlying COPD exacerbations will help to optimize use of the currently available and new interventions for preventing and treating exacerbations. Dove Medical Press 2016-02-19 /pmc/articles/PMC4764047/ /pubmed/26937187 http://dx.doi.org/10.2147/COPD.S85978 Text en © 2016 Pavord et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Pavord, Ian D Jones, Paul W Burgel, Pierre-Régis Rabe, Klaus F Exacerbations of COPD |
title | Exacerbations of COPD |
title_full | Exacerbations of COPD |
title_fullStr | Exacerbations of COPD |
title_full_unstemmed | Exacerbations of COPD |
title_short | Exacerbations of COPD |
title_sort | exacerbations of copd |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4764047/ https://www.ncbi.nlm.nih.gov/pubmed/26937187 http://dx.doi.org/10.2147/COPD.S85978 |
work_keys_str_mv | AT pavordiand exacerbationsofcopd AT jonespaulw exacerbationsofcopd AT burgelpierreregis exacerbationsofcopd AT rabeklausf exacerbationsofcopd |